Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck

This page shows the latest Lundbeck news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’ s drug. Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’. ... Lundbeck says data from the phase II trial is due early next year, while a second trial is also

Latest news

More from news
Approximately 55 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    R&D, this time within psychiatric and neurological treatments, was in the mind of Lundbeck executives when they signed a drug research deal with IBM Watson Health in February. ... Starting with projects in schizophrenia and Parkinson’s disease,

  • Communiqué Awards 2014 Digital Publication Communiqué Awards 2014 Digital Publication

    See which healthcare communications programmes made a real difference to health outcomes with the Communiqué Awards digital publication.

  • The Chinese diabetes challenge The Chinese diabetes challenge

    Last month's ChinaBio Partnering Forum in Suzhou, for example, was sponsored by (among others) AstraZeneca, Bayer, Bristol-Myers Squibb, Johnson &Johnson, Lilly, Lundbeck, Novo Nordisk and Roche.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 030. Chelsea / Lundbeck. Company acquisition. US company with treatments for rare neurologic diseases.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics